- Trial phase
- Approved/Marketed
- Time to market
- Already on the market. The product has been commercially available in the U.S. since at least 2016 and is also sold in Brazil, New Zealand, and other international markets.
- Why 3/10
- Vanguard B Oral is already approved and commercially marketed (USDA-licensed, on the market since at least 2016). There is no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled for this product in the next 12 months. The recent Brazil label expansion (announced November 5, 2026) is a routine commercial update, not a stock-moving binary event. Per the impact score rubric, an approved, marketed drug with no pending regulatory decision scores 3-5, and as a small part of a large diversified portfolio, the score is at the low end.
Vanguard B Oral is a mature, already-commercialized product with no pending regulatory decision or pivotal readout. The next incremental catalyst would be additional geographic label expansions (like the recent Brazil claim), but these are routine commercial updates, not stock-moving binary events. For Zoetis investors, the product is a small contributor within a $9.5B+ revenue portfolio; watch Zoetis's quarterly companion-animal vaccine franchise trends instead.
Price Chart
Executive Summary
Vanguard B Oral is a USDA-licensed, commercially marketed oral vaccine from Zoetis Inc. (NYSE: ZTS) that protects dogs against Bordetella bronchiseptica, a primary cause of kennel cough. It has been on the market since at least 2016 and is the only oral Bordetella vaccine with a USDA-verified 1-year duration of immunity. In November 2026, Zoetis announced an additional label claim for the product in Brazil. However, as a mature product within Zoetis's diversified $9.5B+ revenue portfolio, Vanguard B Oral is not a material standalone driver of Zoetis's stock price, and there are no upcoming binary catalysts (PDUFA dates or pivotal readouts) for this product.
How It Works
Vanguard B Oral is a live, weakened (avirulent) culture of Bordetella bronchiseptica bacteria given by mouth to dogs. It works by stimulating the dog's immune system in the mouth and throat to produce protective antibodies against kennel cough, without causing the disease itself. The vaccine is administered as a 1 mL dose into the cheek pouch, using either a syringe or a syringe-free applicator.
Trial Status
Vanguard B Oral is a USDA-licensed veterinary biological product already in commercial use. A 2026 peer-reviewed study in the American Journal of Veterinary Research confirmed a 7-day onset of immunity in dogs. The product has demonstrated a USDA-verified 1-year duration of immunity.
The Two-Sided Case
Upcoming Catalysts
- Additional international label expansions or regulatory approvals in new geographies (routine, not binary)
- Zoetis quarterly earnings reports (next: Q4 2026 / full-year 2026, expected early February 2027) where Vanguard franchise performance may be mentioned
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zoetis Inc. 8-K ZTS ·Originating report